Literature DB >> 23392639

Experimental autoimmune myasthenia gravis in the mouse.

Bo Wu1, Elzbieta Goluszko, Ruksana Huda, Erdem Tüzün, Premkumar Christadoss.   

Abstract

Myasthenia gravis (MG) is a T cell-dependent antibody-mediated autoimmune neuromuscular disease. Antibodies to the nicotinic acetylcholine receptor (AChR) destroy the AChR, thus leading to defective neuromuscular transmission of electrical impulse and to muscle weakness. This unit is a practical guide to the induction and evaluation of experimental autoimmune myasthenia gravis (EAMG) in the mouse, the animal model for MG. Protocols are provided for the extraction and purification of AChR from the electric organs of Torpedo californica, or the electric ray. The purified receptor is used as an immunogen to induce autoimmunity to AChR, thus causing EAMG. The defect in neuromuscular transmission can also be measured quantitatively by electromyography. In addition, EAMG is frequently characterized by the presence of serum antibodies to AChR, which are measured by radioimmunoassay and by a marked antibody-mediated reduction in the number of muscle AChRs. AChR extracted from mouse muscle is used in measuring serum antibody levels and for quantifying muscle AChR content. Another hallmark of the disease is complement and IgG deposits located at the neuromuscular junction, which can be visualized by immunofluorescence techniques.
© 2013 by John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23392639     DOI: 10.1002/0471142735.im1508s100

Source DB:  PubMed          Journal:  Curr Protoc Immunol        ISSN: 1934-3671


  6 in total

1.  CD1d(hi)CD5+ B cells expanded by GM-CSF in vivo suppress experimental autoimmune myasthenia gravis.

Authors:  Jian Rong Sheng; Songhua Quan; Betty Soliven
Journal:  J Immunol       Date:  2014-08-18       Impact factor: 5.422

2.  Enhancement of T Follicular Helper Cell-Mediated Humoral Immunity Reponses During Development of Experimental Autoimmune Myasthenia Gravis.

Authors:  Ying-Zhe Cui; Si-Ying Qu; Lu-Lu Chang; Jia-Rui Zhao; Lili Mu; Bo Sun; Hu-Lun Li; Tong-Shuai Zhang; Guang-You Wang; Qing-Fei Kong
Journal:  Neurosci Bull       Date:  2019-02-22       Impact factor: 5.203

Review 3.  Review on Toll-Like Receptor Activation in Myasthenia Gravis: Application to the Development of New Experimental Models.

Authors:  Marieke Robinet; Solène Maillard; Mélanie A Cron; Sonia Berrih-Aknin; Rozen Le Panse
Journal:  Clin Rev Allergy Immunol       Date:  2017-02       Impact factor: 8.667

4.  miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice.

Authors:  Lei Shi; Tiantian Liu; Min Zhang; Yapei Guo; Changdong Song; Dandan Song; Hengfang Liu
Journal:  Med Sci Monit       Date:  2015-06-19

Review 5.  Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

Authors:  William D Phillips; Angela Vincent
Journal:  F1000Res       Date:  2016-06-27

Review 6.  Follicular Helper T (Tfh) Cells in Autoimmune Diseases and Allograft Rejection.

Authors:  Yun-Hui Jeon; Youn Soo Choi
Journal:  Immune Netw       Date:  2016-08-23       Impact factor: 6.303

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.